3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Gastrointestinal
2
Dermatologic
2
Breast
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Conditions
Melanoma
4
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Interventions
Cetuximab
44
Oxaliplatin
39
Irinotecan
38
Fluorouracil
36
Capecitabine
36
pembrolizumab
35
Leucovorin
35
Bevacizumab
35
Nivolumab
21
Gemcitabine
17
regorafenib
13
Panitumumab
12
IFL protocol
12
Folfox protocol
12
Cyclophosphamide
12
Pemetrexed
11
Cisplatin
11
tislelizumab
9
Paclitaxel
9
HMPL-013
9
Carboplatin
9
130-nm albumin-bound paclitaxel
8
durvalumab
7
Specimen Handling
7
Docetaxel
7
trametinib
6
Trifluridine
6
Ipilimumab
6
Drug Therapy
6
trifluridine tipiracil drug combination
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colorectal Neoplasms
×
bempegaldesleukin
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts